U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults - Merck
- U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults Merck
- FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections CNBC
- Merck’s vaccine approval poses threat to one of Pfizer’s top-selling products MarketWatch
- New Merck pneumococcal vaccine wins FDA approval STAT
- Merck Wins US Approval for Pneumonia Vaccine to Rival Pfizer's Bloomberg